Psoriasis

Inflammatory Dermatoses No Comments

Treatments

Biologics

Anti-IL-17

Ixekizumab

  • Targets IL-17A
  • Trials – UNCOVER-1, UNCOVER-2, UNCOVER-3 (Ixekizumab treatment for psoriasis¬†, Br J Dermatol 2018; 178:674, DOI:10.1111/bjd.16050)
    • Better than placebo or etanercept
    • Good for fingernail psoriasis
    • Rapid onset – starts to show some benefit in 1 week
    • Approximate PASI improvement after 3 months:
      • About 80% of patients will get at least a 75% improvement
      • About 60% of patients will get at least a 90% improvement
      • About 30% of patients will get a 100% improvement

  • Main side effects – risk of candida infection, possibly flare or cause inflammatory bowel disease